(Q38747872)

6 September 2017

title

Marked for death: targeting epigenetic changes in cancer (English)

1 reference

6 September 2017

Sophia Xiao Pfister

1

1 reference

6 September 2017

Alan Ashworth

series ordinal

2

1 reference

6 September 2017

publication date

10 March 2017

1 reference

Nature Reviews Drug Discovery

6 September 2017

published in

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

241-263

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2016.256

6 September 2017

exact match

0 references

cites work

Epigenetic protein families: a new frontier for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Cancer epigenetics comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNA hypermethylation in tumorigenesis: epigenetics joins genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNA methylation and gene silencing in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Induction of Tumors in Mice by Genomic Hypomethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Aging and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Acquired mutations in TET2 are common in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNA hypomethylation in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Vulnerabilities of mutant SWI/SNF complexes in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

21 January 2018

Targeting EZH2 in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The NSD family of protein methyltransferases in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

TRIM24 links a non-canonical histone signature to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Negative regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family proteins as a mechanism for widespread DNA hypomethylation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone H3 mutations in pediatric brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

ARID1B is a specific vulnerability in ARID1A-mutant cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Romidepsin: a novel histone deacetylase inhibitor for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Regulation of chromatin structure by site-specific histone H3 methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

hDOT1L links histone methylation to leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Synthesis of lysine methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Small-Molecule Targeting of BET Proteins in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

What are super-enhancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Selective inhibition of BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeting MYCN in neuroblastoma by BET bromodomain inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A vaccine targeting mutant IDH1 induces antitumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A rationale to target the SWI/SNF complex for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Stabilization of chromatin structure by PRC1, a Polycomb complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The spectrum of SWI/SNF mutations, ubiquitous in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Dual Chromatin and Cytoskeletal Remodeling by SETD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

CREBBP mutations in relapsed acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Landscape of genomic alterations in cervical carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Harnessing synthetic lethal interactions in anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Gene essentiality and synthetic lethality in haploid human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A landscape of pharmacogenomic interactions in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SET-ting the stage for DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic regulation of immune escape genes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The determinants of tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

An epigenetically altered tumor cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic control of the immune escape mechanisms in malignant carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic targets for immune intervention in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The anticancer effects of HDAC inhibitors require the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

BET inhibitor resistance emerges from leukaemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Cancer: Bet on drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone H3.3 mutations: a variant path to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

EZH2: not EZHY (easy) to deal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Linking of 2-oxoglutarate and substrate binding sites enables potent and highly selective inhibition of JmjC histone demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Up-regulation of DNA methyltransferase 3B expression in endometrial cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

TET proteins and the control of cytosine demethylation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The genetic landscape of mutations in Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Novel mutations target distinct subgroups of medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Non-coding recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The genomic complexity of primary human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

MLL translocations, histone modifications and leukaemia stem-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Hijacked in cancer: the KMT2 (MLL) family of methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone deacetylase 8 in neuroblastoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Histone H3K4me3 Binding Is Required for the DNA Repair and Apoptotic Activities of ING1 Tumor Suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

PHF6 mutations in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

SDH mutations establish a hypermethylator phenotype in paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

21 January 2018

SDH mutations in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Hypomethylation of DNA from benign and malignant human colon neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

New lysine methyltransferase drug targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The Polycomb group protein EZH2 directly controls DNA methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Genetic Interactions in Cancer Progression and Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Synthetic Genetic Array Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

TET2 and DNMT3A mutations in human T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

The landscape of cancer genes and mutational processes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Role of CHD5 in human cancers: 10 years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.256

Augmenting antitumor immune responses with epigenetic modifying agents

31 March 2020

1 reference

12 December 2020

Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis

1 reference

12 December 2020

BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma

1 reference

12 December 2020

Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer

1 reference

12 December 2020

Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster

1 reference

12 December 2020

Mutations and deletions of the CBP gene in human lung cancer.

1 reference

12 December 2020

DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer

1 reference

12 December 2020

Local and global epigenetic regulation of V(D)J recombination

1 reference

12 December 2020

KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs

1 reference

12 December 2020

THE ACTIVITY OF A NEW ANTIMETABOLITE, 5-AZACYTIDINE, AGAINST LYMPHOID LEUKAEMIA IN AK MICE

1 reference

12 December 2020

Cancers and the NSD family of histone lysine methyltransferases.

1 reference

12 December 2020

Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.

1 reference

12 December 2020

Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors

1 reference

12 December 2020

p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.256

1 reference

6 September 2017

1 reference